Blood Coagulants Market 2027 by Types, Application, Technology, Opportunities, End Users and Regions | The Insight Partners

Blood Coagulants Market to 2027 - Global Analysis and Forecasts by Drug class (Non-VKA Oral Anticoagulants (NOACs), Heparin and Low-molecular-weight heparin (LMWH), Vitamin K Antagonist, Others); Route of administration (Oral, Injectable); Bleeding disorder type (Hemophilia A, Hemophilia B, von Willebrand disease (VWD), Others) and Geography

Report Code: TIPRE00004416 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
MARKET INTRODUCTION
Coagulation is the process of converting the blood into a gel like clot to restrict the bleeding. The ability of human body to restrict blood loss during a vascular injury by forming blood clot is vital for healthy body. There are 12 blood coagulation factors involved that leads to the physiological procedure called hemostasis. Hemostasis is the process of clotting involving activation, adhesion, and aggregation of platelets assisted by a number of clotting factors ultimately leads to the injured tissue repairing. Absence of any of these factors can lead to serious blood clotting disorder and uncontrolled bleeding such as, hemophilias and Von Willebrand disease.

MARKET DYNAMICS
Increased prevalence of bleeding disorders, the rising investment in the research activities, the increase in the healthcare project grants provided by public and private organizations, strategic collaborations and new product launches by major players, are few of the factors driving the blood coagulants market. For instance, the World Federation of Hemophilia (WFH) launched a Development Grant Program (DGP) in 2018 to encourage innovative ideas and projects to support the inherited bleeding disorders community globally. However, the lack of awareness regarding blood clotting and the high cost of diagnostic tests, are restraining the growth of blood coagulants market.

MARKET SCOPE
The "Global Blood Coagulants Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of Blood Coagulants market with detailed market segmentation by drug class, route of administration, bleeding disorder type and geography. The global Blood Coagulants market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading Blood Coagulants market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION
The global Blood Coagulants market is segmented on the drug class, route of administration and bleeding disorder type. On the basis of drug class, the global Blood Coagulants market is segmented into Non-VKA Oral Anticoagulants (NOACs), Heparin and Low-molecular-weight heparin (LMWH), Vitamin K Antagonist, and others. On the basis of route of administration, the market is segmented into oral and injectable. On the basis of bleeding disorder type, the Blood Coagulants market is segmented into Hemophilia A, Hemophilia B, von Willebrand disease (VWD) and Others.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Blood Coagulants market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Blood Coagulants market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Blood Coagulants market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Blood Coagulants market in these regions.

MARKET PLAYERS
The reports cover key developments in the Blood Coagulants market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from Blood Coagulants market are anticipated to lucrative growth opportunities in the future with the rising demand for Blood Coagulants in the global market. Below mentioned is the list of few companies engaged in the Blood Coagulants market.

The report also includes the profiles of key Blood Coagulants market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
  • Aspen Holdings
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Baxter International Inc.
  • Daiichi Sankyo Company
  • Grifols International SA, Limited
  • GlaxoSmithKline Plc.
  • Johnson & Johnson (Janssen Pharmaceuticals, Inc)
  • Novo Nordisk A/S
  • Pfizer, Inc.
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.



TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Blood Coagulants Market - By Drug class
1.3.2 Blood Coagulants Market - By Route of administration
1.3.3 Blood Coagulants Market - By Bleeding disorder type
1.3.4 Blood Coagulants Market - By Region
1.3.4.1 By Country
2. KEY TAKEWAYS
3. RESEARCH METHODOLOGY
4. BLOOD COAGULANTS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. BLOOD COAGULANTS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. BLOOD COAGULANTS MARKET - GLOBAL MARKET ANALYSIS
6.1. BLOOD COAGULANTS - GLOBAL MARKET OVERVIEW
6.2. BLOOD COAGULANTS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. BLOOD COAGULANTS MARKET - REVENUE AND FORECASTS TO 2027 - DRUG CLASS
7.1. OVERVIEW
7.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
7.3. NON-VKA ORAL ANTICOAGULANTS (NOACS)
7.3.1. Overview
7.3.2. Non-VKA Oral Anticoagulants (NOACs) Market Forecast and Analysis
7.4. HEPARIN AND LOW-MOLECULAR-WEIGHT HEPARIN (LMWH)
7.4.1. Overview
7.4.2. Heparin and Low-molecular-weight heparin (LMWH) Market Forecast and Analysis
7.5. VITAMIN K ANTAGONIST
7.5.1. Overview
7.5.2. Vitamin K Antagonist Market Forecast and Analysis
7.6. OTHERS
7.6.1. Overview
7.6.2. Others Market Forecast and Analysis
8. BLOOD COAGULANTS MARKET - REVENUE AND FORECASTS TO 2027 - ROUTE OF ADMINISTRATION
8.1. OVERVIEW
8.2. ROUTE OF ADMINISTRATION MARKET FORECASTS AND ANALYSIS
8.3. ORAL
8.3.1. Overview
8.3.2. Oral Market Forecast and Analysis
8.4. INJECTABLE
8.4.1. Overview
8.4.2. Injectable Market Forecast and Analysis
9. BLOOD COAGULANTS MARKET - REVENUE AND FORECASTS TO 2027 - BLEEDING DISORDER TYPE
9.1. OVERVIEW
9.2. BLEEDING DISORDER TYPE MARKET FORECASTS AND ANALYSIS
9.3. HEMOPHILIA A
9.3.1. Overview
9.3.2. Hemophilia A Market Forecast and Analysis
9.4. HEMOPHILIA B
9.4.1. Overview
9.4.2. Hemophilia B Market Forecast and Analysis
9.5. VON WILLEBRAND DISEASE (VWD)
9.5.1. Overview
9.5.2. von Willebrand disease (VWD) Market Forecast and Analysis
9.6. OTHERS
9.6.1. Overview
9.6.2. Others Market Forecast and Analysis
10. BLOOD COAGULANTS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Blood Coagulants Market Overview
10.1.2 North America Blood Coagulants Market Forecasts and Analysis
10.1.3 North America Blood Coagulants Market Forecasts and Analysis - By Drug class
10.1.4 North America Blood Coagulants Market Forecasts and Analysis - By Route of administration
10.1.5 North America Blood Coagulants Market Forecasts and Analysis - By Bleeding disorder type
10.1.6 North America Blood Coagulants Market Forecasts and Analysis - By Countries
10.1.6.1 United States Blood Coagulants Market
10.1.6.1.1 United States Blood Coagulants Market by Drug class
10.1.6.1.2 United States Blood Coagulants Market by Route of administration
10.1.6.1.3 United States Blood Coagulants Market by Bleeding disorder type
10.1.6.2 Canada Blood Coagulants Market
10.1.6.2.1 Canada Blood Coagulants Market by Drug class
10.1.6.2.2 Canada Blood Coagulants Market by Route of administration
10.1.6.2.3 Canada Blood Coagulants Market by Bleeding disorder type
10.1.6.3 Mexico Blood Coagulants Market
10.1.6.3.1 Mexico Blood Coagulants Market by Drug class
10.1.6.3.2 Mexico Blood Coagulants Market by Route of administration
10.1.6.3.3 Mexico Blood Coagulants Market by Bleeding disorder type
10.2. EUROPE
10.2.1 Europe Blood Coagulants Market Overview
10.2.2 Europe Blood Coagulants Market Forecasts and Analysis
10.2.3 Europe Blood Coagulants Market Forecasts and Analysis - By Drug class
10.2.4 Europe Blood Coagulants Market Forecasts and Analysis - By Route of administration
10.2.5 Europe Blood Coagulants Market Forecasts and Analysis - By Bleeding disorder type
10.2.6 Europe Blood Coagulants Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Blood Coagulants Market
10.2.6.1.1 Germany Blood Coagulants Market by Drug class
10.2.6.1.2 Germany Blood Coagulants Market by Route of administration
10.2.6.1.3 Germany Blood Coagulants Market by Bleeding disorder type
10.2.6.2 France Blood Coagulants Market
10.2.6.2.1 France Blood Coagulants Market by Drug class
10.2.6.2.2 France Blood Coagulants Market by Route of administration
10.2.6.2.3 France Blood Coagulants Market by Bleeding disorder type
10.2.6.3 Italy Blood Coagulants Market
10.2.6.3.1 Italy Blood Coagulants Market by Drug class
10.2.6.3.2 Italy Blood Coagulants Market by Route of administration
10.2.6.3.3 Italy Blood Coagulants Market by Bleeding disorder type
10.2.6.4 Spain Blood Coagulants Market
10.2.6.4.1 Spain Blood Coagulants Market by Drug class
10.2.6.4.2 Spain Blood Coagulants Market by Route of administration
10.2.6.4.3 Spain Blood Coagulants Market by Bleeding disorder type
10.2.6.5 United Kingdom Blood Coagulants Market
10.2.6.5.1 United Kingdom Blood Coagulants Market by Drug class
10.2.6.5.2 United Kingdom Blood Coagulants Market by Route of administration
10.2.6.5.3 United Kingdom Blood Coagulants Market by Bleeding disorder type
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Blood Coagulants Market Overview
10.3.2 Asia-Pacific Blood Coagulants Market Forecasts and Analysis
10.3.3 Asia-Pacific Blood Coagulants Market Forecasts and Analysis - By Drug class
10.3.4 Asia-Pacific Blood Coagulants Market Forecasts and Analysis - By Route of administration
10.3.5 Asia-Pacific Blood Coagulants Market Forecasts and Analysis - By Bleeding disorder type
10.3.6 Asia-Pacific Blood Coagulants Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Blood Coagulants Market
10.3.6.1.1 Australia Blood Coagulants Market by Drug class
10.3.6.1.2 Australia Blood Coagulants Market by Route of administration
10.3.6.1.3 Australia Blood Coagulants Market by Bleeding disorder type
10.3.6.2 China Blood Coagulants Market
10.3.6.2.1 China Blood Coagulants Market by Drug class
10.3.6.2.2 China Blood Coagulants Market by Route of administration
10.3.6.2.3 China Blood Coagulants Market by Bleeding disorder type
10.3.6.3 India Blood Coagulants Market
10.3.6.3.1 India Blood Coagulants Market by Drug class
10.3.6.3.2 India Blood Coagulants Market by Route of administration
10.3.6.3.3 India Blood Coagulants Market by Bleeding disorder type
10.3.6.4 Japan Blood Coagulants Market
10.3.6.4.1 Japan Blood Coagulants Market by Drug class
10.3.6.4.2 Japan Blood Coagulants Market by Route of administration
10.3.6.4.3 Japan Blood Coagulants Market by Bleeding disorder type
10.3.6.5 South Korea Blood Coagulants Market
10.3.6.5.1 South Korea Blood Coagulants Market by Drug class
10.3.6.5.2 South Korea Blood Coagulants Market by Route of administration
10.3.6.5.3 South Korea Blood Coagulants Market by Bleeding disorder type
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Blood Coagulants Market Overview
10.4.2 Middle East and Africa Blood Coagulants Market Forecasts and Analysis
10.4.3 Middle East and Africa Blood Coagulants Market Forecasts and Analysis - By Drug class
10.4.4 Middle East and Africa Blood Coagulants Market Forecasts and Analysis - By Route of administration
10.4.5 Middle East and Africa Blood Coagulants Market Forecasts and Analysis - By Bleeding disorder type
10.4.6 Middle East and Africa Blood Coagulants Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Blood Coagulants Market
10.4.6.1.1 South Africa Blood Coagulants Market by Drug class
10.4.6.1.2 South Africa Blood Coagulants Market by Route of administration
10.4.6.1.3 South Africa Blood Coagulants Market by Bleeding disorder type
10.4.6.2 Saudi Arabia Blood Coagulants Market
10.4.6.2.1 Saudi Arabia Blood Coagulants Market by Drug class
10.4.6.2.2 Saudi Arabia Blood Coagulants Market by Route of administration
10.4.6.2.3 Saudi Arabia Blood Coagulants Market by Bleeding disorder type
10.4.6.3 U.A.E Blood Coagulants Market
10.4.6.3.1 U.A.E Blood Coagulants Market by Drug class
10.4.6.3.2 U.A.E Blood Coagulants Market by Route of administration
10.4.6.3.3 U.A.E Blood Coagulants Market by Bleeding disorder type
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Blood Coagulants Market Overview
10.5.2 South and Central America Blood Coagulants Market Forecasts and Analysis
10.5.3 South and Central America Blood Coagulants Market Forecasts and Analysis - By Drug class
10.5.4 South and Central America Blood Coagulants Market Forecasts and Analysis - By Route of administration
10.5.5 South and Central America Blood Coagulants Market Forecasts and Analysis - By Bleeding disorder type
10.5.6 South and Central America Blood Coagulants Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Blood Coagulants Market
10.5.6.1.1 Brazil Blood Coagulants Market by Drug class
10.5.6.1.2 Brazil Blood Coagulants Market by Route of administration
10.5.6.1.3 Brazil Blood Coagulants Market by Bleeding disorder type
10.5.6.2 Argentina Blood Coagulants Market
10.5.6.2.1 Argentina Blood Coagulants Market by Drug class
10.5.6.2.2 Argentina Blood Coagulants Market by Route of administration
10.5.6.2.3 Argentina Blood Coagulants Market by Bleeding disorder type
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. BLOOD COAGULANTS MARKET, KEY COMPANY PROFILES
12.1. ASPEN HOLDINGS
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. BAYER AG
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. BRISTOL-MYERS SQUIBB COMPANY
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. BAXTER INTERNATIONAL INC.
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. DAIICHI SANKYO COMPANY
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. GRIFOLS INTERNATIONAL SA, LIMITED
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. GLAXOSMITHKLINE PLC.
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. JOHNSON AND JOHNSON (JANSSEN PHARMACEUTICALS, INC.)
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. NOVO NORDISK A/S
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. PFIZER, INC.
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies

1. Aspen Holdings
2. Bayer AG
3. Bristol-Myers Squibb Company
4. Baxter International Inc.
5. Daiichi Sankyo Company
6. Grifols International SA, Limited
7. GlaxoSmithKline Plc.
8. Johnson & Johnson (Janssen Pharmaceuticals, Inc. )
9. Novo Nordisk A/S
10. Pfizer, Inc.
Select License Type
USD $3000
USD $4550
USD $6550
USD $8550

Free

20%

customization on Pre-Booking
Pre Book